CORVUS PHARMACEUTICALS, INC. (NASDAQ:CRVS) Files An 8-K Other EventsItem 8.01. Other Events.
On February 1, 2018, Corvus Pharmaceuticals, Inc. issued a press release announcing data from its preclinical study of its novel T-cell signaling pathway inhibitor, in connection with the presentation of such data at the 10th Annual T-Cell Lymphoma Forum. The full text of the press release is filed as Exhibit 99.1 hereto and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
|
99.1 |
Press release titled, “Corvus Pharmaceuticals Announces Presentation of New Data from Preclinical Study of Novel T-Cell Signaling Pathway Inhibitor at 10th Annual T-Cell Lymphoma Forum” dated February 1, 2018. |
Corvus Pharmaceuticals, Inc. ExhibitEX-99.1 2 exh_991.htm PRESS RELEASE EdgarFilingEXHIBIT 99.1Corvus Pharmaceuticals Announces Presentation of New Data from Preclinical Study of Novel T-Cell Signaling Pathway Inhibitor at 10th Annual T-Cell Lymphoma ForumCompany’s Investigational Small Molecule Inhibitor Demonstrates Safety and Activity in Canine Spontaneous T-Cell Lymphoma BURLINGAME,…To view the full exhibit click here
About CORVUS PHARMACEUTICALS, INC. (NASDAQ:CRVS)
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response. The Company’s lead product candidate, CPI-444, is an oral, small molecule antagonist of the A2A receptor for adenosine, an immune checkpoint. Its other products include adenosine production inhibitor (a monoclonal anti-CD73 antibody); adenosine A2B antagonist, and interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. As of September 30, 2016, the Company had not generated any revenue.
